Evotec SE is a global biotechnology company specializing in drug discovery and development. Operating in the pharmaceutical and biotechnology sectors, Evotec collaborates with a wide range of clients, including academic institutions, pharmaceutical companies, and other biotech firms. The company leverages its proprietary technology platforms, such as induced pluripotent stem cells (iPSCs) and machine learning, to enhance the efficiency and effectiveness of drug discovery and development processes. Evotec's business model is based on strategic partnerships and collaborations, where it provides comprehensive R&D services and solutions, from early-stage discovery to clinical development. Revenue is generated through service fees, milestone payments, and royalties from successful drug candidates developed in collaboration with its partners. The company is committed to advancing precision medicine by integrating patient-derived materials and data into its processes, aiming to bring new and better drugs to patients faster and more cost-effectively. Evotec continues to expand its footprint in the United States and Europe, investing in novel cell and gene therapy capabilities and prediction technologies for biologics.

Keywords: biotechnology, drug discovery, development platforms, precision medicine, iPSCs, machine learning, R&D services, strategic partnerships, biologics, gene therapy.